AMENDMENTS TO THE CLAIMS

Please amend Claims 1, 8, 14, 55, 82, 84-85 and 87-88 as shown herein. In addition, please cancel Claims 7, 50-54 and 56-59, and add new Claims 89-99.

1. (CURRENTLY AMENDED) A compound of formula (I)



I

wherein

Z is



in which

R is a hydrogen, a straight-chained or branched alkyl, a straight-chained or branched alkenyl, a straight-chained or branched alkynyl, a cycloalkyl, a cycloalkyl(C_{1-6} alkyl), a lower hydroxyalkyl group, a lower aminoalkyl group, an aralkyl or a heteroaralkyl group;

n is 1;

X_1 is methylene and X_2 is methylene or a bond;

Y_1 is methylene and Y_2 is methylene or a bond;

Ar_1 and Ar_2 independently are unsubstituted or substituted aryl groups or unsubstituted or substituted heteroaryl groups, provided that Ar_1 and Ar_2 are not simultaneously unsubstituted phenyl; and

W is oxygen or sulfur; or

a pharmaceutically acceptable salt ~~or prodrug~~ thereof.

2. (PREVIOUSLY PRESENTED) A compound according to claim 1, wherein R is hydrogen, a straight-chained or branched alkyl, a straight-chained or branched alkenyl, a straight-chained or branched alkynyl, a cycloalkyl, a cycloalkyl(C_{1-6} alkyl) or a lower hydroxyalkyl group.

3. (PREVIOUSLY PRESENTED) A compound according to claim 2, wherein W is oxygen.

4. (ORIGINAL) A compound according to claim 3, wherein

Ar_1 and Ar_2 independently are mono- or disubstituted phenyl groups.

5. (PREVIOUSLY PRESENTED) A compound according to claim 4, wherein

R is a hydrogen, a straight-chained or branched alkyl, a straight-chained or branched alkenyl, a straight-chained or branched alkynyl, a cycloalkyl, or a cycloalkyl(C_{1-6} alkyl);

Y_1 is methylene, Y_2 is a bond or methylene;

X_1 is methylene and X_2 is a bond; and

Ar_1 and Ar_2 are phenyl groups, independently *p*-substituted with groups selected from lower alkyl, lower alkoxy and halogen.

6. (PREVIOUSLY PRESENTED) A compound according to claim 1, having a formula (II)



II

wherein R^N is hydrogen or lower alkyl;

Ar^L is selected from lower alkyl, lower alkoxy and halogen;

Ar^R is selected from lower alkyl, lower alkoxy and halogen;

k is 1 or 2;

and A^- is a suitable anion.

7. (CANCELED)

8. (CURRENTLY AMENDED) A compound of formula (I)



I

wherein

Z is



in which

R is a hydrogen, a straight-chained or branched alkyl, a straight-chained or branched alkenyl, a straight-chained or branched alkynyl, a cycloalkyl, a cycloalkyl(C_{1-6} alkyl), a lower hydroxyalkyl group, a lower aminoalkyl group, an aralkyl or a heteroaralkyl group;

n is 1;

X_1 is methylene and X_2 is methylene or a bond;

Y_1 is methylene and Y_2 is methylene or a bond;

Ar_1 and Ar_2 are different unsubstituted or substituted aryl groups or unsubstituted or substituted heteroaryl groups; and

W is oxygen or sulfur; or

a pharmaceutically acceptable salt ~~or prodrug~~ thereof.

9. (PREVIOUSLY PRESENTED) A compound according to claim 8, wherein R is hydrogen, a straight-chained or branched alkyl, a straight-chained or branched alkenyl, a straight-chained or branched alkynyl, a cycloalkyl, a cycloalkyl(C_{1-6} alkyl) or a lower hydroxyalkyl group.

10. (PREVIOUSLY PRESENTED) A compound according to claim 9, wherein W is oxygen.

11. (ORIGINAL) A compound according to claim 10, wherein

Ar_1 and Ar_2 independently are mono- or disubstituted phenyl groups.

12. (PREVIOUSLY PRESENTED) A compound according to claim 11, wherein

R is a hydrogen, a straight-chained or branched alkyl, a straight-chained or branched alkenyl, a straight-chained or branched alkynyl, a cycloalkyl, or a cycloalkyl(C_{1-6} alkyl);

Y_1 is methylene and Y_2 is a bond or methylene;

X_1 is methylene and X_2 is a bond; and

Ar_1 and Ar_2 are phenyl groups, independently p-substituted with groups selected from alkyl, lower alkoxy and halogen.

13. (PREVIOUSLY PRESENTED) A compound according to claim **[[7]]8**, having a formula (II):



II

wherein R^N is hydrogen or lower alkyl;

Ar^L is selected from lower alkyl, lower alkoxy and halogen;

Ar^R is selected from lower alkyl, lower alkoxy and halogen;

k is 1 or 2;

and A^- is a suitable anion.

14. (CURRENTLY AMENDED) A pharmaceutical composition comprising an effective amount of a compound of formula (I):



I

wherein

Z is



in which

R is a hydrogen, a straight-chained or branched alkyl, a straight-chained or branched alkenyl, a straight-chained or branched alkynyl, a cycloalkyl, or a cycloalkyl(C_{1-6} alkyl), a lower hydroxyalkyl group, a lower aminoalkyl group, an aralkyl or heteroaralkyl group;

n is 1;

X_1 is methylene and X_2 is methylene or a bond;

Y_1 is methylene and Y_2 is methylene or a bond;

Ar_1 and Ar_2 independently are unsubstituted or substituted aryl or heteroaryl groups, provided that Ar_1 and Ar_2 are not simultaneously phenyl; and

W is oxygen or sulfur;

or a pharmaceutically acceptable salt~~, ester or prodrug~~ thereof, and

a pharmaceutically acceptable diluent or excipient.

15. (WITHDRAWN) A method of inhibiting an activity of a monoamine receptor comprising contacting the monoamine receptor or a system containing the monoamine receptor with an amount of one or more of the compounds of claim 1 that is effective in inhibiting the activity of the monoamine receptor.
16. (WITHDRAWN) The method of claim 15 wherein the monoamine receptor is a serotonin receptor.
17. (WITHDRAWN) The method of claim 16 wherein the serotonin receptor is the 5-HT2A subclass.
18. (WITHDRAWN) The method of claim 16 wherein the serotonin receptor is in the central nervous system.
19. (WITHDRAWN) The method of claim 16 wherein the serotonin receptor is in the peripheral nervous system.
20. (WITHDRAWN) The method of claim 16 wherein the serotonin receptor is in blood cells or platelets.
21. (WITHDRAWN) The method of claim 16 wherein the serotonin receptor is mutated or modified.
22. (WITHDRAWN) The method of claim 15 wherein the activity is signaling activity.
23. (WITHDRAWN) The method of claim 15 wherein the activity is constitutive.

24. (WITHDRAWN) The method of claim 15 wherein the activity is associated with serotonin receptor activation.
25. (WITHDRAWN) A method of inhibiting an activation of a monoamine receptor comprising contacting the monoamine receptor or a system containing the monoamine receptor with an amount of a compound of one or more of the compounds of claim 1 that is effective in inhibiting the activation of the monoamine receptor.
26. (WITHDRAWN) The method of claim 25 wherein the activation is by an agonistic agent.
27. (WITHDRAWN) The method of claim 26 wherein the agonistic agent is exogenous.
28. (WITHDRAWN) The method of claim 26 wherein the agonistic agent is endogenous.
29. (WITHDRAWN) The method of claim 25 wherein the activation is constitutive.
30. (WITHDRAWN) The method of claim 25 wherein the monoamine receptor is a serotonin receptor.
31. (WITHDRAWN) The method of claim 30 wherein the serotonin receptor is the 5-HT2A subclass.
32. (WITHDRAWN) The method of claim 30 wherein the serotonin receptor is in the central nervous system.
33. (WITHDRAWN) The method of claim 30 wherein the serotonin receptor is in the peripheral nervous system.
34. (WITHDRAWN) The method of claim 30 wherein the serotonin receptor is in blood cells or platelets.
35. (WITHDRAWN) The method of claim 30 wherein the serotonin receptor is mutated or modified.
36. (WITHDRAWN) A method of treating a disease condition associated with a monoamine receptor comprising administering to a subject in need of such treatment a therapeutically effective amount of one or more of the compounds of claim 1.
37. (WITHDRAWN) The method of claim 36 wherein the disease condition is selected from the group consisting of schizophrenia, psychosis, migraine, hypertension, thrombosis, vasospasm, ischemia, depression, anxiety, sleep disorders and appetite disorders.
38. (WITHDRAWN) The method of claim 36 wherein the disease condition is associated with dysfunction of a monoamine receptor.

39. (WITHDRAWN) The method of claim 36 wherein the disease condition is associated with activation of a monoamine receptor.
40. (WITHDRAWN) The method of claim 36 wherein the disease condition is associated with increased activity of monoamine receptor.
41. (WITHDRAWN) The method of claim 36 wherein the monoamine receptor is a serotonin receptor
42. (WITHDRAWN) The method of claim 41 wherein the serotonin receptor is the 5-HT2A subclass.
43. (WITHDRAWN) The method of claim 41 wherein the serotonin receptor is in the central nervous system.
44. (WITHDRAWN) The method of claim 41 wherein the serotonin receptor is in the peripheral nervous system.
45. (WITHDRAWN) The method of claim 41 wherein the serotonin receptor is in blood cells or platelets.
46. (WITHDRAWN) The method of claim 41 wherein the serotonin receptor is mutated or modified.
47. (WITHDRAWN) A method of treating schizophrenia comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of one or more of the compounds of claim 1.
48. (WITHDRAWN) A method of treating migraine comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of one or more of the compounds of claim 1.
49. (WITHDRAWN) A method of treating psychosis comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of one or more of the compounds of claim 1.
50. (CANCELED)
51. (CANCELED)
52. (CANCELED)
53. (CANCELED)
54. (CANCELED)

55. (CURRENLTY AMENDED) ~~The compound according to claim 1, wherein the~~ A compound **[[is]]** selected from the group consisting of:

~~N-(1-(3,3-dimethylbutyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;~~

~~N-((4-methylphenyl)methyl)-N-(1-(2-methylpropyl)piperidin-4-yl)-4-methoxyphenylacetamide;~~

~~2-(4-methoxyphenyl)-*N*-(4-methylbenzyl)-*N*-(1-methylpiperidin-4-yl)-acetamide;~~

~~2-(4-methoxyphenyl)-*N*-(4-methylbenzyl)-*N*-(1-ethylpiperidin-4-yl)-acetamide;~~

~~2-(4-methoxyphenyl)-*N*-(4-chlorobenzyl)-*N*-(1-ethylpiperidin-4-yl)-acetamide;~~

~~2-(4-methoxyphenyl)-*N*-(4-methylbenzyl)-*N*-(1-isopropylpiperidin-4-yl)-acetamide;~~

~~2-(4-methoxyphenyl)-*N*-(4-chlorobenzyl)-*N*-(1-isopropylpiperidin-4-yl)-acetamide;~~

~~2-(phenyl)-*N*-(4-trifluoromethylbenzyl)-*N*-(1-methylpiperidin-4-yl)-acetamide;~~

~~2-(4-fluorophenyl)-*N*-(4-trifluoromethylbenzyl)-*N*-(1-methylpiperidin-4-yl)-acetamide;~~

~~2-(4-Methoxyphenyl)-*N*-(4-trifluoromethylbenzyl)-*N*-(1-methylpiperidin-4-yl)-acetamide;~~

~~2-(4-Trifluoromethylphenyl)-*N*-(4-trifluoromethylbenzyl)-*N*-(1-methylpiperidin-4-yl)-acetamide;~~

~~2-(4-Fluorophenyl)-*N*-(4-fluorobenzyl)-*N*-(1-methylpiperidin-4-yl)-acetamide;~~

~~2-(4-Methoxyphenyl)-*N*-(4-fluorobenzyl)-*N*-(1-methylpiperidin-4-yl)-acetamide;~~

~~2-(phenyl)-*N*-(4-fluorobenzyl)-*N*-(1-methylpiperidin-4-yl)-acetamide;~~

~~2-(4-Trifluoromethylphenyl)-*N*-(4-fluorobenzyl)-*N*-(1-methylpiperidin-4-yl)-acetamide;~~

~~2-(4-trifluoromethylphenyl)-*N*-[4-(methoxycarbonyl)benzyl]-*N*-(1-methylpiperidin-4-yl)-acetamide;~~

~~2-Phenyl-*N*-[4-(methoxycarbonyl)benzyl]-*N*-(1-methylpiperidin-4-yl)-acetamide;~~

~~2-(4-Chlorophenyl)-*N*-[4-(methoxycarbonyl)benzyl]-*N*-(1-methylpiperidin-4-yl)-acetamide;~~

~~2-(4-Methoxyphenyl)-*N*-[4-(methoxycarbonyl)benzyl]-*N*-(1-methylpiperidin-4-yl) acetamide;~~

2-(4-methoxyphenyl)-N-[2-(4-methylphenyl)ethyl]-N-(1-methylpiperidin-4-yl) acetamide;

2-(4-methoxyphenyl)-N-[2-(4-nitrophenyl)ethyl]-N-(1-methylpiperidin-4-yl) acetamide;

~~2-(4-methoxyphenyl)-*N*-(2-4(fluorophenyl)-ethyl)-*N*-(1-methylpiperidin-4-yl) acetamide;~~

~~2-(4-methoxyphenyl)-*N*-[2-(2,5-dimethoxyphenyl)-ethyl]-*N*-(1-methylpiperidin-4-yl)-acetamide;~~

~~2-(4-methoxyphenyl)-*N*-[2-(2,4-dichlorophenyl)-ethyl]-*N*-(1-methylpiperidin-4-yl) acetamide;~~

~~2-(4-methoxyphenyl)-*N*-[2-(3-chlorophenyl)-ethyl]-*N*-(1-methylpiperidin-4-yl) acetamide;~~

~~2-(4-methoxyphenyl)-*N*-[2-(4-methoxyphenyl)-ethyl]-*N*-(1-methylpiperidin-4-yl) acetamide;~~

~~2-(4-methoxyphenyl)-*N*-[2-(3-fluorophenyl)-ethyl]-*N*-(1-methylpiperidin-4-yl) acetamide;~~

~~2-(4-ethoxyphenyl)-*N*-[2-(4-fluorophenyl)ethyl]-*N*-(1-methylpiperidin-4-yl) acetamide;~~

~~2-(4-ethoxyphenyl)-*N*-(4-fluorobenzyl)-*N*-(1-methylpiperidin-4-yl)-acetamide;~~

N-((4-methylphenyl)methyl)-N-(1-methylpiperidin-4-yl)-2-(3-hydroxyl-4-methoxyphenyl) acetamide;

N-((4-methylphenyl)methyl)-N-(1-methylpiperidin-4-yl)-2-(3,4-dihydroxyphenyl) acetamide;

N-((3-hydroxy-4-methylphenyl)methyl)-N-(1-methylpiperidin-4-yl)-2-(4-methoxyphenyl) acetamide;

N-((4-methylphenyl)methyl)-N-(1-methylpiperidin-4-yl)-2-(4-bromophenyl) acetamide;

N-((4-methylphenyl)methyl)-N-(1-methylpiperidin-4-yl)-2-(4-iodophenyl) acetamide;

N-((4-methylphenyl)methyl)-N-(1-methylpiperidin-4-yl)-2-(4-(2-propyl)phenyl) acetamide;

N-((4-methylphenyl)methyl)-N-(1-methylpiperidin-4-yl)-2-(4-trifluoromethoxyphenyl) acetamide;

N-((4-methylphenyl)methyl)-N-(1-methylpiperidin-4-yl)-2-(4-methylthiophenyl) acetamide;

N-((4-methylphenyl)methyl)-N-(1-methylpiperidin-4-yl)-2-(4-(N,N'-dimethylamino)phenyl) acetamide;

N-((4-methylphenyl)methyl)-N-(1-methylpiperidin-4-yl)-2-(4-nitrophenyl) acetamide;.

N-((4-methylphenyl)methyl)-N-(1-methylpiperidin-4-yl)-2-(4-methoxy-3-methylphenyl) acetamide;

N-((4-methylphenyl)methyl)-N-(1-methylpiperidin-4-yl)-2-(4-methylphenyl) acetamide;

N-((4-(hydroxymethyl)phenyl)methyl)-N-(1-methylpiperidin-4-yl)-2-(4-methoxyphenyl) acetamide;

N-((4-methylphenyl)methyl)-N-(1-phenylmethyl)piperdin-4-yl)-4-methoxyphenylacetamide;

N-((4-methylphenyl)methyl)-N-[(1-phenylmethyl)piperdin-4-yl]-2-(4-methoxyphenyl)thioacetamide;

2-(4-methoxyphenyl)-N-[2-(4-methylphenyl)ethyl]-N-(1-methylpiperdin-4-yl) acetamide;

2-(4-methoxyphenyl)-N-[2-(4-nitrophenyl)ethyl]-N-(1-methylpiperdin-4-yl) acetamide;

2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N-[1-(2-methylthiazol-4-ylmethyl)piperdin-4-yl] acetamide; and

2-(4-methoxyphenyl)-N-(4-chlorobenzyl)-N-(1-methylpiperdin-4-yl) acetamide.

~~2-(4-Chlorophenyl)-N-(4-methylbenzyl)-N-(1-isopropylpiperidin-4-yl)-acetamide;~~

~~2-(4-Chlorophenyl)-N-(4-methylbenzyl)-N-(1-ethylpiperidin-4-yl)-acetamide;~~

~~2-Phenyl-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl)-acetamide~~

~~2-(4-Chlorophenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl)-acetamide;~~

~~2-(4-Fluorophenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl)-acetamide;~~

~~2-(4-Chlorophenyl)-N-(4-methylbenzyl)-N-(1-(2-hydroxyethyl)-piperidin-4-yl)-acetamide;~~

~~2-Phenyl-N-(4-methoxybenzyl)-N-(1-methylpiperidin-4-yl)-acetamide;~~

~~2-(4-Trifluoromethylphenyl)-N-(4-methoxybenzyl)-N-(1-methylpiperidin-4-yl)-acetamide;~~

~~2-(4-Fluorophenyl)-N-(4-methoxybenzyl)-N-(1-methylpiperidin-4-yl)-acetamide;~~

~~2-(4-Methoxyphenyl)-N-(4-methoxybenzyl)-N-(1-methylpiperidin-4-yl)-acetamide;~~

~~2-(4-Methylphenyl)-N-(4-chlorobenzyl)-N-(1-methylpiperidin-4-yl)-acetamide;~~

~~2-(4-Hydroxyphenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl)-acetamide;~~

~~2-(3,4-dimethoxyphenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl)-acetamide;~~

~~2-(4-Methoxyphenyl)-N-(4-methylbenzyl)-N-(1-t-butylpiperidin-4-yl)-acetamide;~~

~~2-(4-Ethoxyphenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl)-acetamide;~~

~~2-(4-Butoxyphenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl)-acetamide;~~ ~~and~~

~~2-(4-i-Propoxyphenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl)-acetamide.~~

56. (CANCELED)

57. (CANCELED)

58. (CANCELED)

59. (CANCELED)

60. (PREVIOUSLY PRESENTED) A compound according to claim 1, wherein

R is a lower alkyl group;

Y_1 is methylene and Y_2 is a bond;

X_1 is methylene and X_2 is a bond; and

Ar_1 and Ar_2 are unsubstituted or substituted phenyl groups.

61. (CANCELED)

62. (CANCELED)

63. (CANCELED)

64. (CANCELED)

65. (CANCELED)

66. (WITHDRAWN) A method of alleviating a condition associated with non-selective antipsychotic compounds comprising administering a therapeutically effective amount of a one or more of the compounds of claim 1 to a subject suffering from said condition.

67. (WITHDRAWN) The method according to claim 66, wherein the compound of claim 1 is a selective antagonist or inverse agonist of a 5-HT2A receptor.

68. (WITHDRAWN) The method of according to claim 66, wherein the compound of claim 1 has little to no activity on other monamine receptors.

69. (WITHDRAWN) The method according to claim 68, wherein one of the other monamine receptors is a dopamine D2 receptor.

70. (WITHDRAWN) The method according to claim 66, wherein Z is

and W is oxygen in the compound of claim 1.

71. (WITHDRAWN) The method according to claim 66, wherein

R is a hydrogen, a lower alkyl group, a cyclic organyl group, or a substituted or unsubstituted aralkyl or heteroaralkyl group;

n is 1;

Y_1 is methylene, Y_2 is a bond, methylene, ethylene, or vinylene;

X_1 is methylene and X_2 is a bond, or X_1 is NH or N(lower alkyl) and X_2 is methylene; and

Ar_1 and Ar_2 are phenyl groups, independently *p*-substituted with groups selected from lower alkyl, lower alkoxy and halogen in the compound of claim 1.

72. (WITHDRAWN) A method of alleviating a condition which is a side effect which can arise in an individual who takes an antipsychotic compound which possess broad activity

at multiple monamine receptors subtypes, comprising administering a therapeutically effective amount of one or more of the compounds of claim 1 to subject suffering from said condition.

73. (WITHDRAWN) The method according to claim 72, wherein the compound of claim 1 is a selective antagonist or inverse agonist of a 5-HT2A receptor.

74. (WITHDRAWN) The method of according to claim 72, wherein the compound of claim 1 has little to no activity on other monamine receptors.

75. (WITHDRAWN) The method according to claim 74, wherein one of the other monamine receptors is a dopamine D2 receptor.

76. (WITHDRAWN) The method according to claim 72, wherein Z is

and W is oxygen in the compound of claim 1.

77. (WITHDRAWN) The method according to claim 72, wherein

R is a hydrogen, a lower alkyl group, a cyclic organyl group, or a substituted or unsubstituted aralkyl or heteroaralkyl group;

n is 1;

Y_1 is methylene, Y_2 is a bond, methylene, ethylene, or vinylene;

X_1 is methylene and X_2 is a bond, or X_1 is NH or N(lower alkyl) and X_2 is methylene; and

Ar_1 and Ar_2 are phenyl groups, independently *p*-substituted with groups selected from lower alkyl, lower alkoxy and halogen in the compound of claim 1.

78. (PREVIOUSLY PRESENTED) A compound according to claim 1, wherein the compound is selected from the group consisting of:

2-(4-methoxyphenyl)-N-[2-(2-thienyl)ethyl]-N-(1-methylpiperidin-4-yl) acetamide;

2-(4-Methoxyphenyl)-N-(2-thienylmethyl)-N-(1-methylpiperidin-4-yl) acetamide;

2-(4-Methoxyphenyl)-N-(furfuryl)-N-(1-methylpiperidin-4-yl) acetamide;

2(2-thienyl)-N-(4-methylphenylmethyl)-N-(1-methylpiperidin-4-yl) acetamide; and

N-((4-methylphenyl)methyl)-N-(1-methylpiperidin-4-yl)-2-(4-pyridyl) acetamide.

79. (PREVIOUSLY PRESENTED) A compound according to claim 1, wherein R is aralkyl and heteroaralkyl.

80. (PREVIOUSLY PRESENTED) A compound according to claim 8, wherein R is aralkyl and heteroaralkyl.

81. (PREVIOUSLY PRESENTED) A compound according to claim 14, wherein R is aralkyl and heteroaralkyl

82. (CURRENTLY AMENDED) A compound according to claim 4, wherein R is a straight-chained or branched alkyl, a straight-chained or branched alkenyl, [[**or**]] a straight-chained or branched alkynyl, a cycloalkyl or a cycloalkyl(C_{1-6} alkyl).

83. (PREVIOUSLY PRESENTED) A compound according to claim 82, wherein Y_1 is methylene and Y_2 is a bond; and X_1 is methylene and X_2 is bond.

84. (CURRENTLY AMENDED) A compound according to claim 83, wherein Ar_1 and Ar_2 are phenyl groups carrying one or more substituents independently ~~, independently p-substituted with groups~~ selected from lower alkyl, lower alkoxy, [[**and**]] halogen, hydroxy, nitro, lower alkylamino, alkylsulfenyl and trifluoromethyl.

85. (CURRENTLY AMENDED) A compound according to claim 11 wherein R is a straight-chained or branched alkyl, a straight-chained or branched alkenyl, [[**or**]] a straight-chained or branched alkynyl, a cycloalkyl or a cycloalkyl(C_{1-6} alkyl).

86. (PREVIOUSLY PRESENTED) A compound according to claim 85, wherein Y_1 is methylene and Y_2 is a bond; and X_1 is methylene and X_2 is bond.

87. (CURRENTLY AMENDED) A compound according to claim 86, wherein Ar_1 and Ar_2 are phenyl groups carrying one or more substituents independently ~~, independently p-substituted with groups~~ selected from lower alkyl, lower alkoxy, [[**and**]] halogen, hydroxy, nitro, lower alkylamino, alkylsulfenyl and trifluoromethyl.

88. (CURRENTLY AMENDED) A compound according to claim 60, wherein Ar_1 and Ar_2 are phenyl groups carrying one or more substituents independently ~~, independently p-~~

~~substituted with groups~~ selected from lower alkyl, lower alkoxy, [[**and**]] halogen, hydroxy, nitro, lower alkylamino, alkylsulfenyl and trifluoromethyl.

89. (NEW) A pharmaceutical composition according to claim 14, wherein R is a straight-chained or branched alkyl, a straight-chained or branched alkenyl, or a straight-chained or branched alkynyl, a cycloalkyl or a cycloalkyl(C_{1-6} alkyl).

90. (NEW) A pharmaceutical composition according to claim 89, wherein Y_1 is methylene and Y_2 is a bond; and X_1 is methylene and X_2 is bond.

91. (NEW) A pharmaceutical composition according to claim 90, wherein Ar_1 and Ar_2 are phenyl groups carrying one or more substituents independently selected from a lower alkyl, lower alkoxy, halogen, hydroxy, nitro, lower alkylamino, alkylsulfenyl and trifluoromethyl.

92. (NEW) A pharmaceutical composition according to claim 91, wherein Ar_1 and Ar_2 are phenyl groups carrying one or more substituents independently selected from a lower alkyl, lower alkoxy and halogen.

93. (NEW) A pharmaceutical composition according to claim 89, wherein W is oxygen.

94. (NEW) A pharmaceutical composition according to claim 93, wherein Ar_1 is an unsubstituted or substituted aryl; and Ar_2 is an unsubstituted or substituted aryl or an unsubstituted or substituted heteroaryl.

95. (NEW) A compound according to claim 3, wherein Ar_1 is an unsubstituted or substituted aryl; and Ar_2 is an unsubstituted or substituted aryl or an unsubstituted or substituted heteroaryl.

96. (NEW) A compound according to claim 84, wherein Ar_1 and Ar_2 are phenyl groups carrying one or more substituents independently selected from a lower alkyl, lower alkoxy and halogen.

97. (NEW) A compound according to claim 10, wherein Ar_1 is an unsubstituted or substituted aryl; and Ar_2 is an unsubstituted or substituted aryl or an unsubstituted or substituted heteroaryl.

98. (NEW) A compound according to claim 87, wherein Ar_1 and Ar_2 are phenyl groups carrying one or more substituents independently selected from a lower alkyl, lower alkoxy and halogen.

99. (NEW) A compound according to claim 88, wherein Ar_1 and Ar_2 are phenyl groups carrying one or more substituents independently selected from a lower alkyl, lower alkoxy and halogen.